This article is more than 5 years old. Information may no longer be current.

MicroShunt similarly reduces IOP in phakic, pseudophakic eyes, and when combined with phaco

Issue: October 10, 2016

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

COPENHAGEN — In glaucomatous eyes implanted with the InnFocus MicroShunt, there was no significant difference in IOP outcomes whether the eyes were phakic or pseudophakic, or when implantation in phakic eyes was combined with phacoemulsification and IOL placement, according to a study presented here.

“This procedure is very simple with immediate and safe reduction of IOP,” Isabella Riss, MD, said at the European Society of Cataract and Refractive Surgeons meeting, where she reported 2-year results of a study comparing outcomes after MicroShunt placement in the three groups of eyes.

Isabella Riss

In the study, 79 patients with mean IOP of 24.8 mm Hg and mean number of medications of 2.3 were implanted with the MicroShunt device, which is CE marked in Europe.

At 2 years, IOP was reduced 47% from baseline to a mean of 13 mm Hg, and more than 70% of eyes had IOP of 14 mm Hg or less, according to Riss.

Overall, there was a 79% reduction in glaucoma medications to 0.6 medications per patient, and 74% of patients were entirely off medication for glaucoma. Hypotony of less than 5 mm Hg after day 1 postoperatively was transient and occurred in 6.3% of cases, although all cases resolved spontaneously. No long-term sight-threatening adverse events, such as endophthalmitis, chronic hypotony or choroidal hemorrhage, were reported.

“The technique of the InnFocus MicroShunt can easily be associated with cataract surgery, and the postop treatment is very similar to the postop treatment of cataract surgery,” Riss said. – by Patricia Nale, ELS

Reference:

Riss I. One and two year results comparing phakic, pseudophakic and combined with cataract surgery cases for the InnFocus MicroShunt. Presented at: 34th Congress of the European Society of Cataract and Refractive Surgeons; Sept. 10-14, 2016; Copenhagen, Denmark.

Disclosure: Riss reports no relevant financial disclosures.